G

Genmab A/S ADS
D

GMAB

22.340
USD
-0.10
(-0.42%)
Market Closed
Volume
58,910
EPS
12
Div Yield
-
P/E
13
Market Cap
14,194,875,989
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    ILMN
    ILMN
    -3.080
    (-3.17%)
    94.180 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    More
News

Title: Genmab A/S ADS

Sector: Healthcare
Industry: Biotechnology
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.